WideCells Group


Published research note on WideCells Group plc

News Release | NewsRoom

Shard Capital have published a research note on WideCells Group plc (WDC : LSE), the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment.

Robin Davison and Dr. Wang Chong from Shard Capital, commented “WideCells’ recent launch of its CellPlan stem cell insurance/medical concierge service marked an important transition for this fast moving company.  In less than one year, WideCells has established a platform to market CellPlan to new and existing umbilical cord blood storage clients and established complementary businesses in stem cell storage/processing, research and education.  WideCells offers an attractive investment opportunity linked to the burgeoning field of stem cell science that is largely without scientific or insurance risk.”

To see the full research note please click here.

**ENDS**

For further information, please visit the Company’s website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

WideCells Group

CEO – João Andrade

Tel:  +351 919 033 171

Smaller Company Capital Ltd

Broker – Jeremy Woodgate & Rupert Williams

Tel: +44 (0) 20 3651 2912

Shard Capital Partners LLP

Broker – Damon Heath & Erik Woolgar

Tel: +44 (0) 207 186 9950

St Brides Partners Ltd

PR – Charlotte Page & Olivia Vita

Tel: +44 (0) 20 7236 1177

Notes to Editors

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable.  In June 2017, the Group was ranked as the 21st most disruptive company globally by DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets.

With this in mind, it has created three divisions:

  • CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process
  • WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.
  • WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

  • Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow – WideCells will focus on promoting the collection and storage of this.
  • Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells
  • 82 illnesses can currently be treated using stem cell procedures
  • Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands

Sources

Shard Capital